ASP Isotopes Inc Dossier - Source-backed chat

ASP Isotopes Inc

ASPINASDAQ

SectorMaterials

IndustrySpecialty Chemicals

Beta (adjusted)2.73

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.65Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $406.3M

Enterprise Value $246.4M

Shares Outstanding 133.6M diluted

Next Earnings Date14 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

ASP Isotopes Inc. (ASPI) is transitioning from a development-stage technology developer to a commercial-scale producer of high-value, scarce isotopes. The company's proprietary Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE) technologies address critical supply constraints across three multi-billion-dollar markets: advanced semiconductors (Silicon-28), nuclear medicine (Carbon-14, Ytterbium-176), and clean energy (HALEU). With commercial shipments of Silicon-28 targeted for Q3 2026 and a robust pipeline of nuclear fuel partnerships (including TerraPower), ASPI offers a high-growth, asymmetric opportunity. While the company continues to incur heavy losses and capital expenditures, its strong balance sheet ($333 million in cash, cash equivalents, and marketable securities as of Dec 31, 2025) provides a multi-year runway to execute its commercialization strategy.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$11.00

Mean target$13.00

High · most bullish analyst$15.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0020%

Technical or engineering bottlenecks delay Silicon-28 and Ytterbium-176 commercial shipments into 2027. High capital intensity and persistent operating losses deplete cash reserves faster than expected, forcing highly dilutive equity raises. Regulatory hurdles or political risks in South Africa stall the development of the HALEU enrichment facilities.

Base CaseCentral scenario

$11.0050%

Silicon-28 shipments commence in late 2026 with minor operational delays. Radiopharmacy revenues double to over $10 million in 2026. The company successfully secures debt financing or strategic partner funding for its advanced isotope plants in South Africa and Iceland, keeping its cash runway stable while advancing the QLE spin-off process.

Bull CaseUpside scenario

$15.0030%

Rapid commercial scale-up of Silicon-28 in Q3 2026 and Ytterbium-176 by late 2026 drives exponential revenue growth. The planned spin-off and U.S. listing of Quantum Leap Energy (QLE) unlocks substantial shareholder value, while definitive HALEU supply agreements with TerraPower and other major energy companies are fully funded by government grants and debt, minimizing equity dilution.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary, highly efficient isotope enrichment technologies (ASP and QE) with significant cost and scalability advantages over traditional centrifuges.
First-mover advantage as a commercial supplier of Silicon-28, a critical material enabling quantum computing and next-generation AI semiconductors.
Strong strategic partnerships in the nuclear energy sector, including a definitive agreement with Bill Gates-backed TerraPower for HALEU supply.
Robust liquidity position with $333 million in cash, cash equivalents, and marketable securities as of December 31, 2025.

Key Investment Risks

High execution and scaling risks as the company transitions from pilot-scale to commercial-scale production across multiple facilities.
Significant concentration of manufacturing operations in South Africa, exposing the company to local infrastructure, regulatory, and political risks.
Persistent high operating losses and capital expenditures, with a net loss of $175.1 million in FY2025.
Dependence on regulatory approvals and licensing for nuclear materials and advanced fuels (HALEU).

Thesis Invalidation Triggers

Failure to initiate commercial shipments of Silicon-28 by the end of 2026.
Termination or material negative modification of the HALEU supply and financing agreements with TerraPower.
Severe regulatory delays or denial of operating licenses for the Pretoria enrichment facilities by South African nuclear regulators.
Rapid depletion of cash reserves leading to unexpected, highly dilutive equity offerings before achieving positive free cash flow.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.